We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Q Therapeutics Selects Goodwin Biotechnology for Manufacturing of Its Monoclonal Antibody
News

Q Therapeutics Selects Goodwin Biotechnology for Manufacturing of Its Monoclonal Antibody

Q Therapeutics Selects Goodwin Biotechnology for Manufacturing of Its Monoclonal Antibody
News

Q Therapeutics Selects Goodwin Biotechnology for Manufacturing of Its Monoclonal Antibody

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Q Therapeutics Selects Goodwin Biotechnology for Manufacturing of Its Monoclonal Antibody"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Q Therapeutics, Inc. (Q) and Goodwin Biotechnology, Inc. (GBI) announced that GBI has begun process development and will be manufacturing a monoclonal antibody used by Q in purifying its cell therapy product, Q-Cells™.

This IgM antibody recognizes a unique cell surface marker that is expressed on Q-Cells (neural glial cells). On successful completion of the production, Q Therapeutics will utilize the IgM antibody to manufacture the Q-Cells in accordance with FDA requirements at a cGMP production facility.

Q Therapeutics anticipates beginning Phase I trials for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis (MS), in 2009.

Advertisement